Literature DB >> 1708695

Coexistence of autologous antibodies and decay-accelerating factor, an inhibitor of complement, on human renal tumor cells.

T Terachi1, G Stanescu, J E Pontes, M E Medof, M J Caulfield.   

Abstract

Autologous immunoglobulin was detected on the cell surface of tumor cells freshly isolated from cancerous kidneys of patients with renal cell carcinoma by flow cytometry after staining with murine anti-human IgG monoclonal antibodies. Cells isolated in parallel from macroscopically normal regions of the tumorous kidneys were not specifically stained with the anti-human IgG reagents. In further studies, tumor cells were stained with an antibody to decay-accelerating factor (DAF), a known inhibitor of complement. Flow cytometry of these cells revealed that nearly all tumor cells expressed DAF, and that the intensity of staining with the anti-DAF monoclonal antibody correlated with the staining of cells with anti-IgG. The results suggest that tumor cells coated with autologous antibody may be resistant to complement-mediated cytotoxicity in vivo through the expression of high levels of DAF.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1708695

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Structural characterization of mouse CD97 and study of its specific interaction with the murine decay-accelerating factor (DAF, CD55).

Authors:  Y M Qian; M Haino; K Kelly; W C Song
Journal:  Immunology       Date:  1999-10       Impact factor: 7.397

2.  Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).

Authors:  G A Niehans; D L Cherwitz; N A Staley; D J Knapp; A P Dalmasso
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

3.  Cell-surface bound complement regulatory activity is necessary for the in vivo survival of KDH-8 rat hepatoma.

Authors:  L Baranyi; K Baranji; H Takizawa; N Okada; H Okada
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

Review 4.  Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.

Authors:  Zvi Fishelson; Michael Kirschfink
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

5.  Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.

Authors:  R Ramajayam; Kian-Pin Tan; Hun-Ge Liu; Po-Huang Liang
Journal:  Bioorg Med Chem       Date:  2010-09-25       Impact factor: 3.641

6.  Decay-accelerating factor (DAF, CD55) in normal colorectal mucosa, adenomas and carcinomas.

Authors:  K Koretz; S Brüderlein; C Henne; P Möller
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.